ErbB2 overexpression portends a poor prognosis and occurs in 25-30% of women with breast cancer.This leads to deregulated growth and survival signaling and mediates resistance to chemo-and hormone therapy.Lapatinib is a highly selective dual inhibitor of ErbB2 (HER2) and ErbB 1 (EGFR) receptor tyrosine kinases which belongs to an important class of drugs and represent a breakthrough in the treatment of breast cancer, we have found that lapatinib inhibits both EGFR and ErbB2 leading to downstream AKT and Erkl/2 pathway inhibition and down regulation of survivin, which result in growth arrest and apoptosis.